Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 Post-Marketing Safety Study of ADVATE in Hemophilia A Patients in India
2022-004149-11Phase 4
- Sponsor
- Takeda
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Takeda. Primary endpoint: Number of Participants With Serious Adverse Events (SAE) Least Possibly Related to ADVATE.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2022-004149-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004149-11.